{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"40","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"A confirmed tumor response is defined to be either a complete response or partial response noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. A complete response (CR) in evaluable patients will be defined as:\n\n* Disappearance of any sign of (evaluable) disease, AND\n* Normalization of CA-125; if CA-125 normalizes, it should be confirmed at any time.\n\nA partial response (PR) in evaluable patients will be defined as:\n\n* Decrement in CA-125 by \\>50%, and\n* Improvement in any additional evaluable disease (if present) as assessed by the enrolling physician.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Everolimus and Letrozole)"}],"paramType":"NUMBER","populationDescription":"All evaluable patients","reportingStatus":"POSTED","timeFrame":"Up to 24 weeks","title":"Confirmed Response Rate, Estimated Using RECIST 1.1 Criteria","type":"SECONDARY","unitOfMeasure":"percentage of patients"}